Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- PMID: 22285168
- DOI: 10.1016/S1470-2045(11)70393-X
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Abstract
Background: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations. We aimed to assess the safety and efficacy of erlotinib compared with standard chemotherapy for first-line treatment of European patients with advanced EGFR-mutation positive NSCLC.
Methods: We undertook the open-label, randomised phase 3 EURTAC trial at 42 hospitals in France, Italy, and Spain. Eligible participants were adults (> 18 years) with NSCLC and EGFR mutations (exon 19 deletion or L858R mutation in exon 21) with no history of chemotherapy for metastatic disease (neoadjuvant or adjuvant chemotherapy ending ≥ 6 months before study entry was allowed). We randomly allocated participants (1:1) according to a computer-generated allocation schedule to receive oral erlotinib 150 mg per day or 3 week cycles of standard intravenous chemotherapy of cisplatin 75 mg/m(2) on day 1 plus docetaxel (75 mg/m(2) on day 1) or gemcitabine (1250 mg/m(2) on days 1 and 8). Carboplatin (AUC 6 with docetaxel 75 mg/m(2) or AUC 5 with gemcitabine 1000 mg/m(2)) was allowed in patients unable to have cisplatin. Patients were stratified by EGFR mutation type and Eastern Cooperative Oncology Group performance status (0 vs 1 vs 2). The primary endpoint was progression-free survival (PFS) in the intention-to-treat population. We assessed safety in all patients who received study drug (≥ 1 dose). This study is registered with ClinicalTrials.gov, number NCT00446225.
Findings: Between Feb 15, 2007, and Jan 4, 2011, 174 patients with EGFR mutations were enrolled. One patient received treatment before randomisation and was thus withdrawn from the study; of the remaining patients, 86 were randomly assigned to receive erlotinib and 87 to receive standard chemotherapy. The preplanned interim analysis showed that the study met its primary endpoint; enrolment was halted, and full evaluation of the results was recommended. At data cutoff (Jan 26, 2011), median PFS was 9·7 months (95% CI 8·4-12·3) in the erlotinib group, compared with 5·2 months (4·5-5·8) in the standard chemotherapy group (hazard ratio 0·37, 95% CI 0·25-0·54; p < 0·0001). Main grade 3 or 4 toxicities were rash (11 [13%] of 84 patients given erlotinib vs none of 82 patients in the chemotherapy group), neutropenia (none vs 18 [22%]), anaemia (one [1%] vs three [4%]), and increased amino-transferase concentrations (two [2%] vs 0). Five (6%) patients on erlotinib had treatment-related severe adverse events compared with 16 patients (20%) on chemotherapy. One patient in the erlotinib group and two in the standard chemotherapy group died from treatment-related causes.
Interpretation: Our findings strengthen the rationale for routine baseline tissue-based assessment of EGFR mutations in patients with NSCLC and for treatment of mutation-positive patients with EGFR tyrosine-kinase inhibitors.
Funding: Spanish Lung Cancer Group, Roche Farma, Hoffmann-La Roche, and Red Temática de Investigacion Cooperativa en Cancer.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Comment in
-
Optimising therapy for EGFR-addicted NSCLC: just the start.Lancet Oncol. 2012 Mar;13(3):216-7. doi: 10.1016/S1470-2045(12)70037-2. Epub 2012 Jan 26. Lancet Oncol. 2012. PMID: 22285167 No abstract available.
Similar articles
-
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.Lancet Oncol. 2013 Jul;14(8):777-86. doi: 10.1016/S1470-2045(13)70254-7. Epub 2013 Jun 17. Lancet Oncol. 2013. PMID: 23782814 Clinical Trial.
-
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.Lancet Oncol. 2011 Aug;12(8):735-42. doi: 10.1016/S1470-2045(11)70184-X. Epub 2011 Jul 23. Lancet Oncol. 2011. PMID: 21783417 Clinical Trial.
-
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.Lancet Oncol. 2014 Feb;15(2):213-22. doi: 10.1016/S1470-2045(13)70604-1. Epub 2014 Jan 15. Lancet Oncol. 2014. PMID: 24439929 Clinical Trial.
-
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.Cochrane Database Syst Rev. 2016 May 25;(5):CD010383. doi: 10.1002/14651858.CD010383.pub2. Cochrane Database Syst Rev. 2016. Update in: Cochrane Database Syst Rev. 2021 Mar 18;3:CD010383. doi: 10.1002/14651858.CD010383.pub3. PMID: 27223332 Updated. Review.
-
Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.J Natl Cancer Inst. 2013 May 1;105(9):595-605. doi: 10.1093/jnci/djt072. Epub 2013 Apr 17. J Natl Cancer Inst. 2013. PMID: 23594426 Review.
Cited by
-
Driver gene alterations in NSCLC patients in southern China and their correlation with clinicopathologic characteristics.Front Genet. 2024 Sep 19;15:1455502. doi: 10.3389/fgene.2024.1455502. eCollection 2024. Front Genet. 2024. PMID: 39364008 Free PMC article.
-
Deciphering the Dynamics of EGFR-TKI Resistance in Lung Cancer: Insights from Bibliometric Analysis.Drug Des Devel Ther. 2024 Sep 26;18:4327-4343. doi: 10.2147/DDDT.S478910. eCollection 2024. Drug Des Devel Ther. 2024. PMID: 39350949 Free PMC article. Review.
-
Cancer Patient-Derived Cell-Based Models: Applications and Challenges in Functional Precision Medicine.Life (Basel). 2024 Sep 10;14(9):1142. doi: 10.3390/life14091142. Life (Basel). 2024. PMID: 39337925 Free PMC article. Review.
-
Combination of Cytologic Findings and Circulating Tumor DNA From Cerebrospinal Fluid Revealed SCLC Transformation in Patients With Leptomeningeal Metastases of Lung Adenocarcinoma.JTO Clin Res Rep. 2024 Jul 6;5(9):100704. doi: 10.1016/j.jtocrr.2024.100704. eCollection 2024 Sep. JTO Clin Res Rep. 2024. PMID: 39282661 Free PMC article.
-
Functional exploration and drug prediction on programmed cell death-related biomarkers in lung adenocarcinoma.Heliyon. 2024 Aug 21;10(17):e36616. doi: 10.1016/j.heliyon.2024.e36616. eCollection 2024 Sep 15. Heliyon. 2024. PMID: 39281570 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous